Combination therapy with a TNF-α inhibitor and an oral immunomodulator is often utilized for patients with rheumatoid arthritis or IBD to enhance the efficacy of the biologic drug, or reduce the risk of immunogenicity [72]. Here, TNF is linked to inflammatory bowel disease.